CMV 2012 - combined 4th Congenital Cytomegalovirus Conference and 14th Internatio
CMV 2012 - 第四届先天性巨细胞病毒会议和第 14 届国际巨细胞病毒会议合并
基本信息
- 批准号:8400272
- 负责人:
- 金额:$ 1.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-01 至 2013-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcademiaAcquired Immunodeficiency SyndromeAffectAngioplastyAntiviral AgentsAreaAtherosclerosisAwardAwarenessBeliefBirthCaliforniaClinicClinicalCollaborationsCongenital AbnormalityCost SavingsCytomegalovirusDevelopmentDiseaseEducational workshopEpidemiologyFacultyFamilyFertilizationFosteringFundingGoalsGovernmentGovernment AgenciesGrantHealthHealth Care CostsHematopoieticHumanImmune responseImmunityImmunocompromised HostImpairmentIndividualIndustryInfantInfectious AgentInfusion proceduresInternationalLaboratoriesLeadMedicalMedical StudentsMedicineMissionMolecularMolecular VirologyMorbidity - disease rateNeonatal ScreeningNewborn InfantOrganPathogenesisPatientsPeer ReviewPhysiciansPlayPostdoctoral FellowPrevalencePreventionResearchResearch PersonnelRoleSan FranciscoScientistSocietiesStudentsTherapeuticTranslational ResearchTranslationsTransplant RecipientsTransplantationTravelVaccinesVascular DiseasesViralVirusVirus-Cell Membrane InteractionWorkabstractingbasecongenital cytomegaloviruscongenital infectioncostcost effectivedisabilityimprovedmeetingsmortalitypathogenpublic educationpublic health relevancerestenosisskillssuccesssymposiumtherapeutic vaccinetherapy developmenttumor
项目摘要
Description (as provided by the applicant): Human cytomegalovirus (HCMV) is the major viral cause of birth defects, and its impact on health care costs is enormous. Approximately 1% of newborns are infected, and of the 13% that are symptomatic at birth, 50% will have permanent impairment. At least 14% of asymptomatic infants will later show disabilities. HCMV is also a serious problem in immunocompromised individuals and has been associated with the development of transplant-associated vascular disease and restenosis following angioplasty. Additionally, it has been proposed that HCMV may play a role in the development of atherosclerosis and the pathogenesis of several types of tumors. The overarching goal of this R13 conference grant is to enable junior investigators (graduate/medical students and postdoctoral fellows, junior faculty) to attend the CMV 2012 Workshop. Travel awards - using funds generated by this application - will be awarded to laboratories of U.S.-based trainees and junior faculty based on peer reviewed scoring of submitted abstracts. CMV 2012 is a unique meeting in that it combines the 4th Congenital CMV Conference and the 14th International CMV/Betaherpesvirus Workshop into a unified conference. The mission of CMV 2012 is to bring together basic scientists, physician scientists, clinicians, representatives from industry and government, and families affected by congenital CMV infection in a forum where there can be a broad exchange of diverse ideas and extensive cross-fertilization of new concepts that lead to a better understanding, prevention, and/or treatment of CMV disease. The increasing emphasis on translational research with the goal of advancing medicine and human health has made it imperative to bring these different groups together. The CMV 2012 Workshop will be held October 29th to November 2nd, 2012 at the Mission Bay Conference Center in San Francisco, California. The areas of focus of both the Congenital CMV Conferences and the International CMV/Betaherpesvirus Workshop will be well-represented at CMV 2012. There are four coequal aims of this meeting. Aim 1 is to facilitate the highest level of scientific excellence with a combination of speakers who are internationally recognized and established leaders in the field, as well as younger investigators whose work is at the cutting edge. Aim 2 emphasizes the research that is highly relevant to important clinical questions and has potential for translation into medical practice. Aim 3 is to foster new collaborations and partnerships between industry, basic and clinical scientists, and government agencies. Aim 4 promotes public education and awareness of the prevalence of congenital CMV infection and impact on society.
Public Health Relevance: Human cytomegalovirus (CMV) is the leading cause of birth defects associated with an infectious agent. Moreover, it is a major cause of morbidity and mortality in immunosuppressed patients, including organ and hematopoietic transplant recipients, and AIDS patients. Significant effort in academia, the clinic and industry is being devoted to improve therapies and develop effective vaccines against these viruses. CMV 2012 will be the preeminent venue devoted solely to the broad range of topics encompassing the clinical, virological, molecular, immunological, and societal aspects of this important human pathogen.
描述(由申请方提供):人巨细胞病毒(HCMV)是导致出生缺陷的主要病毒原因,其对医疗保健成本的影响巨大。大约1%的新生儿被感染,在出生时有症状的13%中,50%将有永久性损伤。至少有14%的无症状婴儿后来会出现残疾。巨细胞病毒在免疫功能低下的个体中也是一个严重的问题,并且与移植相关的血管疾病和血管成形术后再狭窄的发展有关。此外,已经提出HCMV可能在动脉粥样硬化的发展和几种类型的肿瘤的发病机制中起作用。这个R13会议补助金的总体目标是使初级研究人员(研究生/医学生和博士后研究员,初级教师)参加CMV 2012研讨会。旅行奖励-使用本申请产生的资金-将授予美国的实验室-基于学员和初级教师的基础上提交的摘要同行评审评分。CMV 2012是一个独特的会议,它将第四届先天性CMV会议和第十四届国际CMV/β疱疹病毒研讨会合并为一个统一的会议。CMV 2012的使命是将基础科学家、医师科学家、临床医生、来自行业和政府的代表以及受先天性CMV感染影响的家庭聚集在一个论坛中,在该论坛中可以广泛交流不同的想法,并广泛交流新概念,从而更好地理解、预防和/或治疗CMV疾病。随着对以推进医学和人类健康为目标的转化研究的日益重视,将这些不同的群体聚集在一起势在必行。CMV 2012研讨会将于2012年10月29日至11月2日在加州州弗朗西斯科的使命Bay会议中心举行。先天性巨细胞病毒会议和国际巨细胞病毒/β疱疹病毒研讨会的重点领域将在2012年巨细胞病毒大会上得到充分体现。这次会议有四个同等重要的目标。目标1是通过国际公认的、该领域公认的领导者以及工作处于前沿的年轻研究人员的组合,促进最高水平的科学卓越。目标2强调与重要临床问题高度相关的研究,并有可能转化为医疗实践。目标3是促进工业界、基础和临床科学家以及政府机构之间的新的合作和伙伴关系。目的4促进公众教育及认识先天性巨细胞病毒感染的普遍性及其对社会的影响。
公共卫生相关性:人巨细胞病毒(CMV)是与感染因子相关的出生缺陷的主要原因。此外,它是免疫抑制患者(包括器官和造血移植受者)和AIDS患者发病率和死亡率的主要原因。学术界、临床和工业界正在致力于改进治疗方法和开发针对这些病毒的有效疫苗。CMV 2012将是一个卓越的场所,专门致力于广泛的主题,包括临床,病毒学,分子,免疫学和社会方面的这一重要的人类病原体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DEBORAH Hye SPECTOR其他文献
DEBORAH Hye SPECTOR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DEBORAH Hye SPECTOR', 18)}}的其他基金
Zika Virus Pathogenesis and Selective Autophagy Induction to Inhibit Virus Production
寨卡病毒发病机制和选择性自噬诱导抑制病毒产生
- 批准号:
9277152 - 财政年份:2017
- 资助金额:
$ 1.3万 - 项目类别:
Biologic Role of Cytomegalovirus in Endothelial Cell Inflammation and Atheroscler
巨细胞病毒在内皮细胞炎症和动脉粥样硬化中的生物学作用
- 批准号:
8895567 - 财政年份:2014
- 资助金额:
$ 1.3万 - 项目类别:
Role of CMV in Heart Disease of HIV-Infected Women and Perinatally Infected Youth
CMV 在 HIV 感染妇女和围产期感染青少年心脏病中的作用
- 批准号:
8915898 - 财政年份:2014
- 资助金额:
$ 1.3万 - 项目类别:
Disruption of Neural Stem Cell Homeostasis by Cytomegalovirus
巨细胞病毒破坏神经干细胞稳态
- 批准号:
8570815 - 财政年份:2013
- 资助金额:
$ 1.3万 - 项目类别:
Disruption of Neural Stem Cell Homeostasis by Cytomegalovirus
巨细胞病毒破坏神经干细胞稳态
- 批准号:
8661325 - 财政年份:2013
- 资助金额:
$ 1.3万 - 项目类别:
Atherosclerosis: Cytomegalovirus, Shear Stress, and Endothelial Cells
动脉粥样硬化:巨细胞病毒、剪切应力和内皮细胞
- 批准号:
8192010 - 财政年份:2011
- 资助金额:
$ 1.3万 - 项目类别:
Atherosclerosis: Cytomegalovirus, Shear Stress, and Endothelial Cells
动脉粥样硬化:巨细胞病毒、剪切应力和内皮细胞
- 批准号:
8269800 - 财政年份:2011
- 资助金额:
$ 1.3万 - 项目类别:
Development of a Novel Vaccine Against Herpes Simplex Type 2
新型 2 型单纯疱疹疫苗的开发
- 批准号:
7914756 - 财政年份:2009
- 资助金额:
$ 1.3万 - 项目类别:
Disabling of the Anaphase Promoting Complex by Human Cytomegalovirus
人巨细胞病毒使后期促进复合物失活
- 批准号:
7712782 - 财政年份:2009
- 资助金额:
$ 1.3万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 1.3万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 1.3万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 1.3万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 1.3万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 1.3万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 1.3万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 1.3万 - 项目类别:














{{item.name}}会员




